1364632-45-0

Usage

Uses

Used in Pharmaceutical Research and Development:
(S)-(tetrahydrofuran-3-yl)hydrazine hydrochloride is used as an intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs. Its unique structure and properties allow it to be a valuable component in the creation of novel therapeutic agents.
Used in Drug Synthesis:
In the pharmaceutical industry, (S)-(tetrahydrofuran-3-yl)hydrazine hydrochloride is used as a building block for the synthesis of complex organic compounds with potential medicinal properties. Its presence in these compounds can influence their biological activity, making it a key component in drug discovery and design processes.
Used in Biological Activity Studies:
(S)-(tetrahydrofuran-3-yl)hydrazine hydrochloride is utilized in biological assays and screenings to evaluate its potential biological activity. Understanding its interactions with biological systems can provide insights into its therapeutic potential and guide further development as a pharmaceutical agent.
Used in Solubility and Stability Improvements:
In the formulation of pharmaceuticals, (S)-(tetrahydrofuran-3-yl)hydrazine hydrochloride is used to improve the solubility and stability of other compounds in aqueous solutions. This enhancement is crucial for the development of effective drug delivery systems and ensures the compound's efficacy and safety in medical applications.

Upstream product

• 86087-24-3 (R)-3-Hydroxytetrahydrofuran 
• 1429510-92-8 (-)-benzyl 2-(tetrahydrofuran-3-yl)hydrazinecarboxylate 
• 1429510-48-4 (S)-t-butyl 1-(tetrahydrofuran-3-yl)hydrazinecarboxylate 

Downstream Products

• 1429510-43-9 ethyl 5-(4-bromo-2,5-difluorophenyl)-1-[(S)-tetrahydrofuran-3-yl]-1H-pyrazole-4-carboxylate 
• 1429510-33-7 ethyl 5-(4-bromo-2-fluorophenyl)-1-[(S)-tetrahydrofuran-3-yl]-1H-pyrazole-4-carboxylate 
• 1429510-35-9 ethyl 5-(4-bromo-2-nitrophenyl)-1-[(S)-tetrahydrofuran-3-yl]-1H-pyrazole-4-carboxylate 

Relevant academic research and scientific papers

COMPOUNDS USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

SALT OF PYRAZOLOQUINOLINE DERIVATIVE, AND CRYSTAL THEREOF

The present invention provides a salt of (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quinolin-4(5H)-one and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric

PROCESS FOR PRODUCTION OF (S)-(TETRAHYDROFURAN-3-YL)HYDRAZINE

A process for production of (S)-(tetrahydrofuran-3-yl)hydrazine of formula I or an acid addition salt thereof, comprising hydrolysis or hydrogenation step of protected hydrazine compound of formula VII, wherein Ra is a tert-butyl group or a benzyl group, is disclosed. (S)-(Tetrahydrofuran-3-yl)hydrazine of formula I or an acid addition salt thereof is a useful intermediate in the preparation of a PDE9 inhibitor.

PYRAZOLOQUINOLINE DERIVATIVES

A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has applicability as a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.